Stock Scorecard
Stock Summary for Akebia Therapeutics Inc (AKBA) - $1.37 as of 1/22/2026 6:36:03 PM EST
Total Score
8 out of 30
Safety Score
33 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for AKBA
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for AKBA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for AKBA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for AKBA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for AKBA (33 out of 100)
| Stock Price Rating (Max of 10) | 2 |
| Historical Stock Price Rating (Max of 10) | 1 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 2 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for AKBA
Financial Details for AKBA
Company Overview |
|
|---|---|
| Ticker | AKBA |
| Company Name | Akebia Therapeutics Inc |
| Country | USA |
| Description | Akebia Therapeutics, Inc. (AKBA), based in Cambridge, Massachusetts, is a leading biopharmaceutical company focused on the development and commercialization of innovative therapies for chronic kidney disease. The firm has established a strong pipeline targeting significant unmet needs within renal care, leveraging advanced research methodologies and forming strategic partnerships to optimize treatment outcomes. With a dedicated mission to enhance patient quality of life and a commitment to pioneering advancements in renal health, Akebia is strategically positioned to make a meaningful impact in the evolving healthcare landscape. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - SPECIALTY & GENERIC |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/12/2026 |
Stock Price History |
|
| Last Day Price | 1.37 |
| Price 4 Years Ago | 0.58 |
| Last Day Price Updated | 1/22/2026 6:36:03 PM EST |
| Last Day Volume | 2,105,535 |
| Average Daily Volume | 2,962,143 |
| 52-Week High | 4.08 |
| 52-Week Low | 1.30 |
| Last Price to 52 Week Low | 5.38% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 39.77 |
| Sector PE | 103.82 |
| 5-Year Average PE | 3.45 |
| Free Cash Flow Ratio | 2.17 |
| Industry Free Cash Flow Ratio | 9.46 |
| Sector Free Cash Flow Ratio | 27.30 |
| Current Ratio Most Recent Quarter | 1.94 |
| Total Cash Per Share | 0.63 |
| Book Value Per Share Most Recent Quarter | 0.16 |
| Price to Book Ratio | 8.58 |
| Industry Price to Book Ratio | 14.74 |
| Sector Price to Book Ratio | 19.79 |
| Price to Sales Ratio Twelve Trailing Months | 1.58 |
| Industry Price to Sales Ratio Twelve Trailing Months | 3.10 |
| Sector Price to Sales Ratio Twelve Trailing Months | 21.86 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 265,366,000 |
| Market Capitalization | 363,551,420 |
| Institutional Ownership | 49.98% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -33.67% |
| Reported EPS 12 Trailing Months | -0.08 |
| Reported EPS Past Year | 0.05 |
| Reported EPS Prior Year | -0.33 |
| Net Income Twelve Trailing Months | -15,905,000 |
| Net Income Past Year | -69,410,000 |
| Net Income Prior Year | -51,925,000 |
| Quarterly Revenue Growth YOY | 57.00% |
| 5-Year Revenue Growth | -13.72% |
| Operating Margin Twelve Trailing Months | 7.57% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 166,444,000 |
| Total Cash Past Year | 51,870,000 |
| Total Cash Prior Year | 42,925,000 |
| Net Cash Position Most Recent Quarter | 118,803,000 |
| Net Cash Position Past Year | 13,177,000 |
| Long Term Debt Past Year | 38,693,000 |
| Long Term Debt Prior Year | 17,183,000 |
| Total Debt Most Recent Quarter | 47,641,000 |
| Equity to Debt Ratio Past Year | 0.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.47 |
| Total Stockholder Equity Past Year | -49,185,000 |
| Total Stockholder Equity Prior Year | -30,584,000 |
| Total Stockholder Equity Most Recent Quarter | 41,592,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 32,174,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 0.12 |
| Free Cash Flow Past Year | -40,692,000 |
| Free Cash Flow Prior Year | -23,384,000 |
Options |
|
| Put/Call Ratio | 0.02 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 0.36 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 1/21/2026 4:55:21 PM EST |